Opinion statement
Despite their rarity, angiosarcomas are one of the most aggressive soft tissue sarcomas. Management can often be challenging due to their location and infiltrative nature. A multidisciplinary treatment approach is always warranted, but the recurrence remains high even for localized tumors despite multimodality treatment. In the metastatic setting, cytotoxic chemotherapies, targeted therapies, and, more recently, immunotherapy are used. The sequence of systemic therapies remains currently a topic of active investigation. Over the last couple of years, there have been significant advances in understanding angiosarcoma biology, most notably via patient-driven initiatives like the Angiosarcoma Project. The knowledge derived from such translational work has led to identifying potential biomarkers of response to treatments and exploring new therapeutic avenues. More clinical trials are underway to expand treatment options and improve patient outcomes.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Antonescu C. Malignant vascular tumors—an update. Mod Pathol. 2014;27:S30–8.
Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD, et al. Angiosarcoma: clinical and molecular insights. Ann Surg. 2010 Jun;251(6):1098–106.
Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma: a report of 67 patients and a review of the literature. Cancer. 1996;77(11):2400–6.
Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010 Oct;11(10):983–91.
Gaballah AH, Jensen CT, Palmquist S, Pickhardt PJ, Duran A, Broering G, et al. Angiosarcoma: clinical and imaging features from head to toe. Br J Radiol. 2017;90(1075):20170039.
Florou V, Wilky BA. Current and future directions for angiosarcoma therapy. Curr Treat Options in Oncol. 2018;19(3):14.
•• Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, et al. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020;26(2):181–7 Results of the highly impactful Angiosarcoma Project in terms of expanding the knowledge on angiosarcoma at the tumor genomic level.
Boichard A, Wagner MJ, Kurzrock R. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing. Genome Med. 2020;12(1):61.
Chan JY, Lim JQ, Yeong J, Ravi V, Guan P, Boot A, et al. Multiomic analysis and immune profiling reveal distinct subtypes of human angiosarcoma. J Clin Invest. 2020;130(11):5833–46.
Weidema ME, van de Geer E, Koelsche C, Desar IME, Kemmeren P, Hillebrandt-Roeffen MHS, et al. DNA methylation profiling identifies distinct clusters in angiosarcomas. Clin Cancer Res. 2020;26(1):93–100.
Co M, Lee A, Kwong A. Cutaneous angiosarcoma secondary to lymphoedema or radiation therapy — a systematic review. Clin Oncol. 2019 Apr;31(4):225–31.
Palmerini E, Leithner A, Windhager R, Gosheger G, Boye K, Laitinen M, et al. Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS). Sci Rep. 2020;10(1):10853.
Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18(12):2030–6.
Heinhuis KM, IJzerman NS, van der Graaf WTA, Kerst JM, Schrage Y, Beijnen JH, et al. Neoadjuvant systemic treatment of primary angiosarcoma. Cancers (Basel). 2020;12(8):2251.
Constantinidou A, Sauve N, Stacchiotti S, Blay J-Y, Vincenzi B, Grignani G, et al. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020;5(4):e000787.
• Roy A, Gabani P, Davis EJ, Oppelt P, Merfeld E, Keedy VL, et al. Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma. Clin Transl Radiat Oncol. 2021:114–20. First report on efficacy of concurrent chemoradiation in localized cutaneous angiosarcoma, that may change the standard approach in this setting if findings are confirmed in the ongoing phase II study.
Young RJ, Natukunda A, Litière S, Woll PJ, Wardelmann E, Van Der Graaf WTA. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer. 2014;50(18):3178–86.
D'Angelo SP, Munhoz RR, Kuk D, Landa J, Hartley EW, Bonafede M, et al. Outcomes of systemic therapy for patients with metastatic angiosarcoma. Oncology. 2015;89(4):205–14.
Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly Paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26(32):5269–74.
Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008;44(16):2433–6.
Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86(10):2034–7.
Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian rare cancer network. Ann Oncol. 2012;23(2):501–8.
Tian Z, Zhang F, Li P, Wang J, Yang J, Zhang P, et al. Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma. BMC Cancer. 2020;20(1):698.
Fujisawa Y, Fujimura T, Matsushita S, Yamamoto Y, Uchi H, Otsuka A, et al. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study. Br J Dermatol. 2020 Nov 26;183(5):831–9.
Ravi V, Wagner M, Chen TW-W, Loong HHF, Mennel RG, Yen C-C, et al. A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma. J Clin Oncol. 2020;38(15_suppl):11517.
Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, et al. Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209(3):507–20.
Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97(1):74–81.
Zietz C, Rössle M, Haas C, Sendelhofert A, Hirschmann A, Stürzl M, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998;153(5):1425–33.
Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24(1):257–63.
Ray-Coquard IL, Domont J, Tresch-Bruneel E, Bompas E, Cassier PA, Mir O, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: A randomized phase II trial. J Clin Oncol. 2015;33(25):2797–802.
Dickson MA, D'Adamo DR, Keohan ML, D'Angelo SP, Carvajal RD, Gounder MM, et al. Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma. Sarcoma. 2015;2015:532478.
Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol (Madr). 2017;56(1):88–92.
von Mehren M, Litwin S, Ravi V, Schuetze S, Movva S, Agulnik M, et al. Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS). J Clin Oncol. 2019;37(15_suppl):11039.
Ravi V, Sanford EM, Wang W-L, Ross JS, Ramesh N, Futreal A, et al. Antitumor response of VEGFR2- and VEGFR3-amplified angiosarcoma to pazopanib. J Natl Compr Canc Netw. 2016;14(5):499–502.
Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1732–42.
Agulnik M, Robinson SI, Okuno SH, Siontis B, Attia S, Kocherginsky M, et al. Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma. J Clin Oncol. 2020;38(15_suppl):11561.
Jones R, Ravi V, Brohl AS, Chawla SP, Ganjoo K, Italiano A, et al. Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS). Ann Oncol [Internet]. 2019 Oct;30:v683.
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65.
Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother cancer. 2019;7(1):213.
• Florou V, Espejo Freire A, Goel N, Rosenberg AE, Wilky BA, Trent JC. Safety and efficacy of immune checkpoint inhibitors in patients with angiosarcoma. In: CTOS Annual Meeting. 2019. First case series describing the use and efficacy of immune checkpoint inhibitors in patients with angiosarcoma.
Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy—a case report. J Immunother cancer. 2017;5(1):58.
Momen S, Fassihi H, Davies HR, Nikolaou C, Degasperi A, Stefanato CM, et al. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Mol Case Stud. 2019;5(5):a004408.
Hamacher R, Kämpfe D, Reuter-Jessen K, Pöttgen C, Podleska LE, Farzaliyev F, et al. Dramatic response of a PD-L1–positive advanced angiosarcoma of the scalp to pembrolizumab. JCO Precis Oncol. 2018;16(2):1–7.
Wagner M, Othus M, Patel S, Ryan C, Sangal A, Powers B, et al. 795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2020;8(Suppl 3):A843.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Vaia Florou declares that she has no conflict of interest.
Breelyn A. Wilky has received compensation from SpringWorks and Deciphera for service as a consultant.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Skin Cancer
Rights and permissions
About this article
Cite this article
Florou, V., Wilky, B.A. Current Management of Angiosarcoma: Recent Advances and Lessons From the Past. Curr. Treat. Options in Oncol. 22, 61 (2021). https://doi.org/10.1007/s11864-021-00858-9
Accepted:
Published:
DOI: https://doi.org/10.1007/s11864-021-00858-9